Clinical Trials Browser

Phase 1 × Carcinoma, Squamous Cell × durvalumab × Clear all

NCT03381183 2025-12-05

IRX-2 Regimen and Durvalumab, for Incurable H&N Squamous Cell Carcinoma

Phase 1 Completed

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell